UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology.


Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
28 09 2023
Historique:
medline: 2 10 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.

Identifiants

pubmed: 37769033
pii: 28514
doi: 10.18632/oncotarget.28514
pmc: PMC10538703
doi:

Substances chimiques

Uridine Diphosphate Glucose Dehydrogenase EC 1.1.1.22
Uridine Diphosphate Glucose V50K1D7P4Y
Glucose IY9XDZ35W2
Glucose Dehydrogenases EC 1.1.1.-

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

843-857

Subventions

Organisme : NIDCR NIH HHS
ID : R01 DE031053
Pays : United States

Références

J Biol Chem. 2010 Nov 19;285(47):36721-35
pubmed: 20843787
Biochemistry. 2012 Nov 20;51(46):9364-74
pubmed: 23106432
Nature. 2018 Nov;563(7732):584-588
pubmed: 30420606
Biomolecules. 2021 Feb 09;11(2):
pubmed: 33572239
FEBS Lett. 2005 May 9;579(12):2722-6
pubmed: 15862315
Int J Mol Med. 2015 Jul;36(1):113-22
pubmed: 26005723
J Cell Mol Med. 2020 Oct;24(20):11883-11902
pubmed: 32893977
Genes Dis. 2021 Sep 17;9(3):717-730
pubmed: 35782977
Mol Cancer. 2011 Mar 23;10:30
pubmed: 21429221
Cancer. 2014 Jun 15;120(12):1800-9
pubmed: 24668563
Protein Pept Lett. 2006;13(8):859-62
pubmed: 17073734
Biochem Soc Trans. 2019 Jun 28;47(3):945-955
pubmed: 31189734
Biochem Soc Trans. 2010 Oct;38(5):1378-85
pubmed: 20863317
Arch Biochem Biophys. 2009 Jun 1;486(1):35-43
pubmed: 19358821
J Cell Physiol. 2011 Mar;226(3):749-61
pubmed: 20717929
Chem Biol Interact. 2016 Jan 25;244:195-203
pubmed: 26721195
Cell Mol Life Sci. 2016 Aug;73(16):3183-204
pubmed: 26883802
J Biol Chem. 1977 Feb 25;252(4):1320-6
pubmed: 557038
Br J Cancer. 2011 Dec 6;105(12):1839-49
pubmed: 22045192
Matrix Biol. 2019 May;78-79:147-164
pubmed: 29709595
Biomolecules. 2020 Nov 07;10(11):
pubmed: 33171800
Nature. 2019 Jul;571(7763):127-131
pubmed: 31243371
Oncogene. 2018 May;37(20):2615-2629
pubmed: 29479058
Biochemistry. 2014 Dec 30;53(51):8043-51
pubmed: 25478983
J Histochem Cytochem. 2021 Jan;69(1):13-23
pubmed: 32749901
ACS Omega. 2019 Sep 24;4(15):16318-16329
pubmed: 31616809
J Histochem Cytochem. 2021 Jan;69(1):35-47
pubmed: 32623953
J Biochem Mol Biol. 2007 Sep 30;40(5):690-6
pubmed: 17927902
Oncol Lett. 2016 Nov;12(5):3250-3258
pubmed: 27899990
PLoS One. 2011;6(10):e25226
pubmed: 21984906
Cell Biochem Funct. 1990 Oct;8(4):211-20
pubmed: 2272119
J Biochem. 2013 Nov;154(5):395-408
pubmed: 24092768
Front Immunol. 2015 May 06;6:201
pubmed: 25999946
Exp Cell Res. 2010 Oct 15;316(17):2893-902
pubmed: 20691680
Pathol Oncol Res. 2020 Apr;26(2):1029-1039
pubmed: 30972633
Int J Oncol. 2017 Jan;50(1):5-14
pubmed: 27878243
J Enzyme Inhib Med Chem. 2016 Dec;31(6):1492-7
pubmed: 26903444
Cancer Chemother Pharmacol. 2006 Jan;57(2):165-70
pubmed: 16341905
Biotechnol Lett. 2005 Aug;27(16):1229-32
pubmed: 16158268
Histochem Cell Biol. 2012 Dec;138(6):895-911
pubmed: 22825838
Horm Cancer. 2016 Aug;7(4):260-71
pubmed: 27307252
Cell Microbiol. 2008 Dec;10(12):2447-60
pubmed: 18717819
Tokai J Exp Clin Med. 1990 May;15(2-3):167-77
pubmed: 2130525
Neoplasma. 1990;37(5):501-10
pubmed: 2234212
Int J Cancer. 2010 Jan 15;126(2):315-27
pubmed: 19676054
J Biol Chem. 1975 Nov 25;250(22):8761-7
pubmed: 171263
Cancer Lett. 2020 Nov 1;492:21-30
pubmed: 32768525
Int J Cancer. 2012 Jan 15;130(2):454-66
pubmed: 21387290
Anticancer Res. 2009 Aug;29(8):2981-5
pubmed: 19661304
Biochemistry. 2011 Jun 28;50(25):5780-9
pubmed: 21595445
Oncogene. 2020 Apr;39(15):3089-3101
pubmed: 31308490
FEBS Lett. 2008 Nov 12;582(27):3793-7
pubmed: 18930055
Front Oncol. 2021 Sep 30;11:711642
pubmed: 34660277
Cell. 2003 Sep 19;114(6):727-37
pubmed: 14505572
Cancer Res. 2010 Apr 1;70(7):2613-23
pubmed: 20332231

Auteurs

Meghan J Price (MJ)

Department of Internal Medicine, John Hopkins Hospital, Baltimore, MD 21287, USA.

Annee D Nguyen (AD)

Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA.

Jovita K Byemerwa (JK)

Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27708, USA.

Jasmine Flowers (J)

Department of Neurosurgery, Associated with Duke University Medical Center, Durham, NC 27710, USA.

César D Baëta (CD)

Department of Epidemiology and Clinical Research, Stanford University, Stanford, CA 94305, USA.

C Rory Goodwin (CR)

Department of Neurosurgery, Duke Center for Brain and Spine Metastasis and Duke Cancer Institute, Durham, NC 27710, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH